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Abstract
Objective
To synthesise evidence on the average bias and heterogeneity associated with reported
methodological features of randomized trials.
Design
Systematic review of meta-epidemiological studies.
Methods
We retrieved eligible studies included in a recent AHRQ-EPC review on this topic (latest
search September 2012), and searched Ovid MEDLINE and Ovid EMBASE for studies
indexed from Jan 2012-May 2015. Data were extracted by one author and verified by
another. We combined estimates of average bias (e.g. ratio of odds ratios (ROR) or differ-
ence in standardised mean differences (dSMD)) in meta-analyses using the random-effects
model. Analyses were stratified by type of outcome (“mortality” versus “other objective” ver-
sus “subjective”). Direction of effect was standardised so that ROR < 1 and dSMD < 0
denotes a larger intervention effect estimate in trials with an inadequate or unclear (versus
adequate) characteristic.
Results
We included 24 studies. The available evidence suggests that intervention effect estimates
may be exaggerated in trials with inadequate/unclear (versus adequate) sequence genera-
tion (ROR 0.93, 95% CI 0.86 to 0.99; 7 studies) and allocation concealment (ROR 0.90,
95% CI 0.84 to 0.97; 7 studies). For these characteristics, the average bias appeared to be
larger in trials of subjective outcomes compared with other objective outcomes. Also,
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intervention effects for subjective outcomes appear to be exaggerated in trials with lack of/
unclear blinding of participants (versus blinding) (dSMD -0.37, 95% CI -0.77 to 0.04; 2 stud-
ies), lack of/unclear blinding of outcome assessors (ROR 0.64, 95% CI 0.43 to 0.96; 1
study) and lack of/unclear double blinding (ROR 0.77, 95% CI 0.61 to 0.93; 1 study). The
influence of other characteristics (e.g. unblinded trial personnel, attrition) is unclear.
Conclusions
Certain characteristics of randomized trials may exaggerate intervention effect estimates.
The average bias appears to be greatest in trials of subjective outcomes. More research on
several characteristics, particularly attrition and selective reporting, is needed.
Introduction
Randomized clinical trials (RCTs) are considered to produce the most credible estimates of the
effects of interventions [1–3]. For this reason, they are often used to inform health care and
policy decisions, either directly or via their inclusion in systematic reviews. However, interven-
tion effect estimates in RCTs can be biased due to flaws in the design and conduct of the study,
which can lead to an overestimation or underestimation of the true intervention effect. Such
bias can potentially result in ineffective and harmful interventions being implemented into
practice, and effective interventions not being implemented. Authors of systematic reviews of
RCTs are therefore encouraged to assess the risk of bias in the included RCTs and to incorpo-
rate these assessments into the analysis and conclusions [4].
Empirical evidence can inform which methodological features of RCTs should be consid-
ered when appraising RCTs. Many studies have investigated the influence of reported study
design characteristics on intervention effect estimates following the landmark study by Schulz
et al. [5], which found that trials with inadequate allocation concealment and no double blind-
ing yielded more beneficial estimates of intervention effects. Two syntheses of these studies
were recently published. A US Agency for Healthcare Research and Quality (AHRQ) report
summarised the results of 38 studies [6]. The authors concluded that some aspects of trial con-
duct may exaggerate intervention effect estimates, but that most estimates of bias were impre-
cise and inconsistent between studies. However, they made little distinction between the
included studies in terms of their sample size and methodological rigor, and the heterogeneity
in average bias estimates within the studies was not examined. A rapid systematic review
reached a conclusion similar to the AHRQ review [7], but only three characteristics (sequence
generation, allocation concealment and blinding) were examined, while other theoretically
important features such as attrition and selective outcome reporting were not.
The aim of this systematic review was to synthesise the results of meta-epidemiological
studies that have investigated the average bias and heterogeneity associated with reported
methodological features of RCTs.
Materials and Methods
All methods were pre-specified in a study protocol, which is available in S1 Appendix. This
review is reported according to the PRISMA Statement [8] (see S1 PRISMA Checklist).
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Eligibility criteria
Types of studies. We included meta-epidemiological studies investigating the association
between reported methodological characteristics and intervention effect estimates in RCTs. We
considered only meta-epidemiological studies adopting a matched design that ensured that com-
parisons between trials with different methodological features were only made within the same
clinical scenario. Matching is most often done at the meta-analysis level, when a collection of
meta-analyses is assembled and the individual trials within each meta-analysis are classified into
those with or without a particular methodological characteristic (such as adequate versus inade-
quate allocation concealment) [9,10]. Matching can also be done at the trial level. For example, a
collection of trials is assembled and different measures of the same outcome in each trial are clas-
sified into those with or without a characteristic (such as blinded versus unblinded assessment of
the same outcome). Or, a multi-arm trial includes a blinded sub-study (such as experimental ver-
sus placebo control) and an unblinded sub-study (such as experimental versus no-treatment con-
trol) [11]. We included meta-epidemiological studies regardless of the clinical focus (e.g. type of
condition, intervention and outcome) or analysis methods used by the investigators.
We excluded single systematic reviews and meta-analyses of RCTs that present a subgroup
or sensitivity analysis based on a particular source of bias, since the influence of reported study
characteristics on intervention effect estimates tends to be estimated imprecisely within indi-
vidual meta-analyses. We also excluded studies that assembled a collection of RCTs (e.g. all
child health related RCTs published in 2012), and used meta-regression to examine the rela-
tionship between a source of bias and trial effect estimates. Such studies do not control for the
different interventions examined and outcomes measured across the trials, and so are at high
risk of bias due to confounding. Finally, we excluded meta-epidemiological studies comparing
randomized with non-randomized studies.
Types of methodological features. We only included meta-epidemiological studies inves-
tigating methodological features that can lead to the biases under the conceptual framework
that underlies the Cochrane risk of bias tool for RCTs (see Fig 1, Table 1). We included meta-
epidemiological studies regardless of how the sources of bias were assessed/defined by the
study authors. For example, older meta-epidemiological studies may have used the Jadad scale
[12] to assess blinding while more recent meta-epidemiological studies may have used the
Cochrane risk of bias tool [13]. Further, some meta-epidemiological studies may have catego-
rised RCTs based on whether “double” or “single” or no blinding was performed, while other
studies may have assessed which parties (e.g. patients, trial personnel) were blinded. We
excluded meta-epidemiological studies of the association between other characteristics and
intervention effect estimates in RCTs (e.g. industry sponsorship [14], sample size [15], single
versus multi-centre status [16,17], stopping trials early for benefit or harm [18], and country of
enrolment [19]).
Estimates of interest. Our primary interest was in the association between each methodo-
logical characteristic and:
1. the magnitude of the intervention effect estimate (average bias);
2. variation in average bias across meta-analyses (to determine whether average bias estimates
are relatively similar or not across meta-analyses addressing different clinical questions),
and;
3. the extent of between-trial heterogeneity associated with each characteristic (to determine,
for example, whether effect estimates from inadequately concealed trials are more likely to
be heterogeneous than estimates from adequately concealed trials). We were also interested
in the above estimates stratified by type of outcome (e.g. “mortality” versus “other objective”
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versus “subjective”) and type of intervention (e.g. “pharmacological” versus “non-pharma-
cological”), however defined by the study authors. We could not include estimates stratified
by type of comparator (e.g. placebo versus no treatment) since such estimates were not
reported in any of the included studies. We included meta-epidemiological studies which
presented at least one of the estimates of interest.
Fig 1. Conceptual framework that underlies the Cochrane risk of bias tool for RCTs. Letters A-E denote the sources of bias listed in Table 1.
doi:10.1371/journal.pone.0159267.g001
Table 1. Eligible sources of bias in randomized trials.
Type of bias Possible methodological features that can lead to bias
A. Bias arising from the
randomisation process
Inadequate generation of a random sequence
Inadequate allocation concealment
Imbalance in baseline characteristics
No adjustment for confounding in the analysis
B. Bias due to deviations from
intended interventions
Non-blinded participants
Non-blinded clinician/treatment provider
Unbalanced delivery of additional interventions or co-interventions
Participants switching interventions within the trial and being
analysed in a group different from the one to which they were
randomized
C. Bias due to missing/incomplete
outcome
Missing/incomplete outcome data (dropouts, losses to follow-up, or
post-randomisation exclusions)
D. Bias in measurement of outcomes Non-blinded outcome assessor
Non-blinded data analyst
Use of faulty measurement instruments (with low validity and
reliability)
E. Bias in selection of the reported
result
Selective reporting of a subset of outcome domains, or of a subset of
outcome measures or analyses for a particular outcome domain.
doi:10.1371/journal.pone.0159267.t001
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Search strategy
We retrieved all meta-epidemiological studies included in the AHRQ report, which searched
for studies published up to September 2012 [6]. To identify more recent meta-epidemiological
studies, we searched Ovid MEDLINE (Jan 2012 to May 2015) and Ovid EMBASE (Jan 2012 to
May 2015). We also searched the Cochrane Database of Systematic Reviews for all reviews
edited by the Methodology Review Group (on 20 May 2015), and abstract books of the 2011–
2014 Cochrane Colloquia (available at http://abstracts.cochrane.org/) and of the 2011 and 2013
Clinical Trials Methodology Conference (available at http://www.trialsjournal.com/
supplements/12/S1/all and http://www.trialsjournal.com/supplements/14/S1/all). Search strat-
egies are presented in S1 Appendix. We reviewed the reference lists of all included meta-epide-
miological studies to identify additional meta-epidemiological studies. We also reviewed the
list of studies included in two other relevant reviews [7,20].
Study selection
One reviewer (MJP) screened all titles and abstracts retrieved from the searches. Two reviewers
(MJP and GC) independently screened all full text articles retrieved. Any disagreements
regarding study eligibility were resolved via discussion
Data extraction and management
One reviewer (MJP) extracted all of the data using a form developed in Microsoft Excel. A sec-
ond reviewer (GC) verified the accuracy of all average bias and heterogeneity effect estimates
and confidence limits extracted. Data extraction items are presented in S1 Appendix. We did
not contact study authors to retrieve any missing data about the study methods and results.
The following data were extracted:
• study characteristics, including the methodological characteristics investigated, how the
characteristic was assessed (i.e. number of authors involved in assessment, inter-rater reli-
ability of assessment), definitions of adequate/inadequate characteristics, number of
included meta-analyses, number of RCTs included in the meta-analyses, sampling frame
(e.g. “random sample of all Cochrane reviews with continuous outcomes that included at
least 3 RCTs”), areas of health care addressed, and range of years of publication of the
meta-analyses;
• types of outcomes, interventions and comparators examined in the meta-analyses (which
were categorised using the classification systems described by Savović et al. [10,21], when suf-
ficient information about each was provided);
• effect estimates and measures of precision (e.g. ratio of odds ratio (ROR) and 95% confidence
interval (95% CI);
• any confounding variables assessed by the study authors (e.g. sample size, other methodolog-
ical characteristics);
• any methods used to deal with potential overlap of RCTs across the meta-analyses.
Statistical analyses
Characteristics of included meta-epidemiological studies were summarised using frequencies
and percentages for binary variables and medians and interquartile ranges (IQRs) for continu-
ous variables.
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We analysed the association between a methodological characteristic and the magnitude of an
intervention effect estimate (average bias) using the ratio of odds ratios (ROR), ratio of hazard
ratios (RHR), or difference in standardised mean differences (dSMD) effect measure, whichever
was reported by the study investigators. We analysed the association between a methodological
characteristic and between-trial heterogeneity, and the variation in average bias, using the stan-
dard deviation of underlying effects (tau) or I2. We only analysed associations for each character-
istic independently (i.e. we did not consider average bias in trials with both inadequate allocation
concealment and lack of double blinding, or in trials rated at “overall high risk of bias”).
We combined estimates of average bias in a meta-analysis using the random-effects model.
We used DerSimonian and Laird’s method of moments estimator to estimate the between-
study variance [22]. We assessed statistical inconsistency by inspecting forest plots and calcu-
lating the I2 statistic [23]. When methodological characteristics were defined differently across
the meta-epidemiological studies, we presented average bias effect estimates of each study on
forest plots, but did not combine these in a meta-analysis. We presented average bias estimates
for all outcomes, subgroups of outcomes (e.g. mortality, other objective, subjective), and sub-
groups of interventions (e.g. pharmacological, non-pharmacological) where available. To
synthesise average bias estimates for binary and continuous outcomes, we converted dSMDs to
log RORs by multiplying by π/
p
3 = 1.814 [24]. The direction of effect was standardised so that
a ROR< 1 and dSMD< 0 denotes a larger intervention effect estimate in trials with an inade-
quate or unclear (versus adequate) characteristic.
Two studies combined data from individual meta-epidemiological studies [10,25]. Wood
et al. [25] combined data from three meta-epidemiological studies [5,26,27] while the
BRANDO study [10] combined data from these same three meta-epidemiological studies
along with four others [28–31]. To avoid double counting we included only the BRANDO esti-
mate in our meta-analyses. The BRANDO investigators ensured that if any meta-analyses
appeared in more than one of the seven meta-epidemiological studies, the duplicate meta-anal-
yses were removed (i.e. meta-analyses could not be contributed by more than one of the indi-
vidual meta-epidemiological studies). We also presented average bias estimates, where
available, from the seven contributing meta-epidemiological studies in the forest plots for
transparency. Results fromWood et al. are excluded from both forest plots and meta-analyses.
Based on the clinical conditions and publication dates of meta-analyses/trials examined in the
other meta-epidemiological studies included in our review, we believe that the frequency of
overlapping meta-analyses/trials in our meta-analyses is likely to be small.
Some meta-epidemiological studies presented multiple comparisons and analyses for the
same outcome. We used the following decision rules to select effect estimates to present in for-
est plots:
• comparisons selected in the following order: (1) inadequate/unclear versus adequate (or
“high/unclear” versus “low” risk of bias); (2) inadequate versus adequate; (3) inadequate ver-
sus adequate/unclear.
• adjusted effect estimate selected ahead of unadjusted effect estimate.
Results
Results of the search
A total of 3081 records were identified in the searches. We retrieved 118 full text articles after
screening 2910 unique titles/abstracts. Twenty-four meta-epidemiological studies summarised
in 28 reports met the inclusion criteria (Fig 2) [5,10,11,21,25–48]. A list of excluded studies is
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Fig 2. Flow diagram of identification, screening, and inclusion of trials.
doi:10.1371/journal.pone.0159267.g002
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presented in S1 Appendix. Of the 90 excluded studies, the majority were either not meta-epide-
miological studies using a matched design or investigated an ineligible study design character-
istic. We also identified five ongoing studies [49–53].
Characteristics of included studies
The included meta-epidemiological studies were published between 1995 and 2015 (Table 2).
Matching was done at the meta-analysis level in 20 meta-epidemiological studies (e.g. individ-
ual trials within each meta-analysis were classified into those with or without allocation con-
cealment), and at the trial level in four meta-epidemiological studies (e.g. individual outcomes
within each trial were classified as measured by a blinded assessor or a non-blinded assessor)
[11,39–41]. Meta-epidemiological studies included a median of 26 meta-analyses (published
from 1983 to 2014) with a median 229 trials (published from 1955 to 2011). The majority of
meta-epidemiological studies included meta-analyses/trials addressing a range of clinical con-
ditions, interventions and outcome types rather than restricting inclusion to a particular clini-
cal area. However, the proportion of each type of condition, intervention and outcome varied
considerably across the meta-epidemiological studies (Table 2; characteristics of each individ-
ual study are presented in S1 Appendix). The most commonly assessed methodological charac-
teristics were allocation concealment, sequence generation and double blinding. Average bias
associated with methodological characteristics was reported in all meta-epidemiological stud-
ies. In contrast, increase in between-trial heterogeneity and variation in average bias were
reported in only one [21] and 11 meta-epidemiological studies [11,21,32,33,38–41,44–46],
respectively. In the majority of meta-epidemiological studies, binary outcomes were analysed,
using the meta-meta-analytic approach (where average bias estimates are first derived for each
individual meta-analysis, and then combined using a meta-analysis model that can allow for
between- and within-meta-analysis heterogeneity) [9]. The issue of non-independence of data
(which can occur when the same trial is included in more than one meta-analysis in a study)
was avoided or addressed in the analysis in most meta-epidemiological studies (Table 2).
Average bias and heterogeneity associated with methodological
characteristics
Estimates of average bias were available for 13 methodological characteristics, of which nine
were assessed in more than one meta-epidemiological study (see forest plots in figures below;
single study estimates for other characteristics are summarised in the text). Heterogeneity esti-
mates were reported for only six characteristics (Table 3). The criteria used to classify charac-
teristics (i.e. as adequate/unclear/inadequate) were similar across the meta-epidemiological
studies for all characteristics except for attrition (definitions used in each study are presented
in S1 Appendix). Intervention subgroup estimates (e.g. drug trials versus non-drug trials) of
average bias and heterogeneity are presented in S1 Appendix.
Bias arising from the randomisation process. Based on a meta-analysis of seven meta-
epidemiological studies [21,33–35,37,42,46], inadequate/unclear (versus adequate) sequence
generation was associated with a 7% exaggeration of intervention effect estimates on average
(ROR 0.93, 95% CI 0.86 to 0.99; I2 0%; Fig 3). The bias appears to be greater in trials of subjec-
tive outcomes (ROR 0.90, 95% CI 0.80 to 1.01; I2 0%; 4 meta-epidemiological studies
[21,33,37,46]) compared with trials of other objective outcomes (ROR 0.98, 95% CI 0.84 to
1.15; I2 0%; 4 meta-epidemiological studies [21,33,37,46]), although the 95% CIs overlap. Inad-
equate/unclear (versus adequate) sequence generation led to only a small increase in between-
trial heterogeneity within the meta-analyses in the BRANDO study. The variation in average
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Table 2. Summary of characteristics of includedmeta-epidemiological studies.
Characteristics Studies (%,
n = 24)
Type of meta-epidemiological study
Assembled a collection of meta-analyses, and compared (within each meta-analysis)
the effect estimate in trials with versus without a characteristic
20 (83)
Assembled a collection of trials, and compared (within each trial) the effect estimate for
the same outcome with versus without a characteristic
3 (13)
Othera 1 (4)
Methodological characteristics examined
Sequence generation 14 (58)
Allocation concealment 17 (71)
Baseline imbalance 3 (13)
Adjusting for confounders in analysis 1 (4)
Block randomisation in unblinded trials 1 (4)
Blinding of participants 6 (25)
Blinding of personnel 3 (13)
Participants switching intervention groups within the trial 1 (4)
Attrition 10 (42)
Blinding of outcome assessor 7 (29)
Blinding of data analyst 1 (4)
Double blinding 11 (46)
Selective reporting 3 (13)
Method of assessing methodological characteristics
Two reviewers independently assessed all trials 18 (75)
Reliance on assessments by authors of included meta-analyses 4 (17)
One reviewer assessed all trials, with veriﬁcation by another 1 (4)
Only one author assessed all trials 1 (4)
Outcomes measured
Average bias 24 (100)
Extent of between-trial heterogeneity 1 (5)b
Variation in average bias 11 (46)
Number of includedmeta-analyses/trials
Median (IQR) meta-analyses 26 (16–46)
Median (IQR) trials 229 (116–380)
Year of publication of included meta-analyses/trials
Range for meta-analyses 1983–2014
Range for trials 1955–2011
Area of health care of includedmeta-analyses/trials
Varied 16 (67)
Child/neonatal health only 2 (8)
Osteoarthritis only 2 (8)
Mental health only 1 (4)
Oral medicine only 1 (4)
Pregnancy and childbirth only 1 (4)
Critical care medicine only 1 (4)
Type of experimental intervention in included meta-analyses/trials
Varied (pharmacologic or non-pharmacologic) 21 (88)
Pharmacologic only 1 (4)
Non-pharmacologic only 2 (8)
(Continued)
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bias across meta-analyses was minimal in two meta-epidemiological studies [21,33], but high
in the study of oral medicine meta-analyses [46] (Table 3).
Our meta-analysis of seven meta-epidemiological studies [21,33–35,37,38,42] suggests that
intervention effect estimates tends to be exaggerated by 10% in trials with inadequate/unclear
(versus adequate) allocation concealment (ROR 0.90, 95% CI 0.84 to 0.97; I2 28%; Fig 4). The
average bias was greatest in trials of subjective outcomes (ROR 0.80, 95% CI 0.71 to 0.90; I2 0%;
4 meta-epidemiological studies [21,33,37,44]), and in trials of complementary and alternative
medicine interventions (CAM) (Dsmd -0.52 versus -0.01 in non-CAM trials; 1 meta-epidemio-
logical study [44]; S1 Appendix). Little evidence of bias in trials of mortality or other objective
outcomes was observed (ROR 1.02 and 1.03, respectively). There was only a limited increase in
between-trial heterogeneity and limited variation in average bias in the BRANDO study,
whereas variation in average bias was high in three smaller meta-epidemiological studies
[33,38,44] (Table 3).
Table 2. (Continued)
Characteristics Studies (%,
n = 24)
Type of outcome in included meta-analyses/trials
Varied (mortality, other objective or subjective) 18 (75)
Mortality only 1 (4)
Subjective only 5 (21)
Type of outcomemeasure in includedmeta-analyses/trials
Binary 16 (67)
Continuous 7 (29)
Time-to-event 1 (4)
Analysis approach usedc
Meta-meta-analytic approach [9] 17 (71)
Logistic regression 4 (17)
Multivariable, multilevel model [47] 3 (13)
Bayesian hierarchical bias model 2 (8)
Bayesian network meta-regression model 1 (4)
No modelling 1 (4)
How non-independence of data was addressed
Dependent trials excluded 12 (50)
Dependent trials included, but analysis adjusted to account for this 6 (25)
Unclear (dependent trials possibly included) 5 (21)
Dependent trials included, with no adjustment for this 1 (4)
All values given as n (%) except where indicated.
a Assembled a collection of trials, and compared (within each trial) the effect estimate in sub-studies with
versus without a characteristic. Speciﬁcally, investigators included parallel group four-armed clinical trials
that randomized patients to a blinded sub-study (experimental vs control) and an otherwise identical nonblind
sub-study (experimental vs control). Investigators also included three-armed trials with experimental and no-
treatment groups and a placebo group portrayed to patients as another experimental group, so that patients
were not informed about the possibility of a placebo intervention. This permitted the experimental group to be
included both in a nonblind sub-study (experimental vs no treatment control) and a blind sub-study
(experimental vs placebo control)
b Denominator is 20 as between-trial heterogeneity is not applicable in four meta-epidemiological studies
c Percentages do not sum to 100 as some meta-epidemiological studies used more than one approach
doi:10.1371/journal.pone.0159267.t002
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Table 3. Heterogeneity associated with methodological characteristics.
Study design characteristic Average bias (95%
CI)
Increase in between-trial heterogeneity*
(95% CI)
Variation in average bias
(95% CI)
Inadequate/unclear sequence generation (versus
adequate)
Armijo-Olivo 2015: All outcomes dSMD -0.02 (-0.15,
0.12)
NR tau 0.10
BRANDO (Savović 2012): All outcomes ROR 0.90 (0.82,
0.99)
tau 0.06 (0.01, 0.20) tau 0.05 (0.01, 0.15)
BRANDO (Savović 2012): Mortality ROR 0.86 (0.69,
1.06)
tau 0.08 (0.01, 0.31) tau 0.06 (0.01, 0.28)
BRANDO (Savović 2012): Other objective ROR 1.00 (0.84,
1.20)
tau 0.07 (0.01, 0.30) tau 0.07 (0.01, 0.27)
BRANDO (Savović 2012): Subjective ROR 0.88 (0.76,
1.00)
tau 0.05 (0.01, 0.21) tau 0.06 (0.01, 0.24)
Papageorgiou 2015: All outcomes dSMD -0.01 (-0.26,
0.25)
NR tau 0.46
Inadequate/unclear allocation concealment
(versus adequate)
Armijo-Olivo 2015: All outcomes dSMD -0.12 (-0.30,
0.06)
NR tau 0.21
BRANDO (Savović 2012): All outcomes ROR 0.89 (0.81,
0.99)
tau 0.06 (0.01, 0.19) tau 0.05 (0.01, 0.18)
BRANDO (Savović 2012): Mortality ROR 1.03 (0.82,
1.31)
tau 0.07 (0.01, 0.30) tau 0.07 (0.01, 0.33)
BRANDO (Savović 2012): Other objective ROR 0.92 (0.76,
1.12)
tau 0.06 (0.01, 0.24) tau 0.06 (0.01, 0.29)
BRANDO (Savović 2012): Subjective ROR 0.82 (0.70,
0.94)
tau 0.08 (0.01, 0.27) tau 0.07 (0.01, 0.30)
Herbison 2011: All outcomes ROR 0.91 (0.83,
0.99)
NR tau 0.19
Nuesch 2009a: Subjective outcomes dSMD -0.15 (-0.31,
0.02)
NR tau 0.24
Lack of/unclear blinding of participants (versus
blinding)
Hrobjartsson 2014b: Subjective dSMD -0.56 (-0.71,
-0.41)
NA I2 60%
Nuesch 2009a: Subjective dSMD -0.15 (-0.39,
0.09)
NR tau 0.26
Lack of/unclear blinding of outcome assessor
(versus blinding)
Hrobjartsson 2012: Subjective ROR 0.64 (0.43,
0.96)
NA I2 45%
Hrobjartsson 2013: Subjective dSMD -0.23 (-0.40,
-0.06)
NA I2 46%
Hrobjartsson 2014a: Subjective (standard trials) RHR 0.73 (0.57,
0.93)
NA I2 24%
Hrobjartsson 2014a: Subjective (atypical trials) RHR 1.33 (0.98,
1.82)
NA I2 0%
Lack of/unclear double blinding (versus double
blinding)
BRANDO (Savović 2012): All outcomes ROR 0.86 (0.73,
0.98)
tau 0.20 (0.02, 0.39) tau 0.17 (0.03, 0.32)
BRANDO (Savović 2012): Mortality ROR 1.07 (0.78,
1.48)
tau 0.09 (0.01, 0.44) tau 0.08 (0.01, 0.42)
(Continued)
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The influence of other sources of bias arising from the randomisation process were less
clear. There was little evidence that the presence (versus absence) of baseline imbalance inflates
intervention effects (ROR 1.03, 95% CI 0.89 to 1.19; I2 0%; 2 meta-epidemiological studies
[29,37]; Fig 5); this lack of association was found regardless of the type of outcome, but all esti-
mates were very imprecise. Also, there was little evidence that intervention effect estimates
were exaggerated in trials without (versus with) adjustment for confounders (ROR 0.96, 95%
CI 0.79 to 1.23; 1 meta-epidemiological study [29]), or which used (versus did not use) block
randomisation in unblinded trials (dSMD -0.18, 95% CI -0.47 to 0.11; 1 meta-epidemiological
study [37]). However, each characteristic was only examined in a single small meta-epidemio-
logical study (with at most 26 meta-analyses).
Bias due to deviations from intended interventions. Based on a meta-analysis of three meta-
epidemiological studies [29,34,35] examining objective and subjective outcomes together, there was
little evidence of bias in trials with lack of/unclear blinding of participants (versus blinding of par-
ticipants) (ROR 0.92, 95% CI 0.81 to 1.04; I2 0%; Fig 6)). No association was also found in single
meta-epidemiological studies examining trials of mortality [35] or other objective outcomes [41].
However, intervention effects appear to be exaggerated in trials with subjectively measured out-
comes (dSMD -0.37, 95% CI -0.77 to 0.04; I2 88%; 2 meta-epidemiological studies [41,44]). The
average bias was larger in the meta-epidemiological study by Hrobjartsson et al. (dSMD -0.56)
compared with Nuesch et al. (dSMD -0.15), in acupuncture trials (dSMD -0.63) versus non-acu-
puncture trials (dSMD -0.17), and in non-drug trials (dSMD -0.67) versus drug trials (dSMD 0.04)
(S1 Appendix). Inconsistency in average bias was moderate in one meta-epidemiological study (I2
60% [41]) and the magnitude of heterogeneity was high in another (tau 0.26 [44]) (Table 3).
Intervention effect estimates for binary outcomes were not exaggerated in trials with lack
of/unclear blinding of personnel (versus blinding of personnel) (ROR 1.00, 95% CI 0.86 to
Table 3. (Continued)
Study design characteristic Average bias (95%
CI)
Increase in between-trial heterogeneity*
(95% CI)
Variation in average bias
(95% CI)
BRANDO (Savović 2012): Other objective ROR 0.91 (0.64,
1.33)
tau 0.10 (0.01, 0.50) tau 0.20 (0.02, 0.85)
BRANDO (Savović 2012): Subjective ROR 0.77 (0.61,
0.93)
tau 0.24 (0.02, 0.45) tau 0.20 (0.04, 0.39)
Attrition (versus no or minimal attrition)
Abraha 2015: All outcomes ROR 0.80 (0.69,
0.94)
NR tau 0.28
Abraha 2015: Objective ROR 0.80 (0.60,
1.06)
NR tau 0.42
Abraha 2015: Subjective ROR 0.84 (0.70,
1.01)
NR tau 0.33
BRANDO (Savović 2012): All outcomes ROR 1.07 (0.92,
1.25)
tau 0.07 (0.01, 0.24) tau 0.06 (0.01, 0.24)
BRANDO (Savović 2012): Mortality ROR 1.07 (0.80,
1.42)
tau 0.10 (0.01, 0.32) tau 0.09 (0.01, 0.75)
BRANDO (Savović 2012): Other objective ROR 1.35 (0.63,
2.94)
tau 0.13 (0.01, 1.05) tau 0.13 (0.01, 1.15)
BRANDO (Savović 2012): Subjective ROR 1.03 (0.79,
1.36)
tau 0.07 (0.01, 0.38) tau 0.07 (0.01, 0.35)
* tau is on the log scale for RORs, but not for dSMDs
CI = conﬁdence interval; dSMD = difference in standardised mean differences; NA = not applicable; NR = not reported; RHR = ratio of hazard ratios;
ROR = ratio of odds ratios. dSMD < 0 and ROR and RHR < 1 = larger effect in trials with inadequate characteristic (or at high/unclear risk of bias)
doi:10.1371/journal.pone.0159267.t003
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Fig 3. Random-effects meta-analysis of RORs associated with inadequate/unclear (versus adequate) sequence generation. The boxed
section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a study
(however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis with
adjustment for allocation concealment and double blinding [the corresponding univariable ROR is (95%CrI) 0.89 (0.82, 0.96)]. The BRANDO 2012b
ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR (95%
CrI) is 0.89 (0.75, 1.05)]. The Unverzagt 2013c ROR is based on a multivariable analysis with adjustment for allocation concealment, double blinding,
attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient
follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.98 (0.8, 1.21)]. The BRANDO 2012d ROR is based
on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR (95%CrI) is 0.99
(0.84, 1.16)]. The BRANDO 2012e ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the
corresponding univariable ROR (95% CrI) is 0.83 (0.74, 0.94)].
doi:10.1371/journal.pone.0159267.g003
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Fig 4. Random-effects meta-analysis of RORs associated with inadequate/unclear (versus adequate) allocation concealment. The boxed
section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a study
(however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis with
adjustment for sequence generation and double blinding [the corresponding univariable ROR (95%CrI) is 0.93 (0.87, 0.99)]. The BRANDO 2012b ROR
is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.98
(0.88, 1.10)]. The BRANDO 2012c ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the
corresponding univariable ROR (95% CrI) is 0.97 (0.85, 1.10)]. The BRANDO 2012d ROR is based on a multivariable analysis with adjustment for
sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.85 (0.75, 0.95)].
doi:10.1371/journal.pone.0159267.g004
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1.16; I2 0%; 2 meta-epidemiological studies [29,34]; Fig 7). A similar lack of effect on continu-
ous outcomes was found in trials with lack of/unclear blinding of participants or personnel
(versus blinding of either party) (dSMD 0.00, 95% CI -0.09 to 0.09; 1 meta-epidemiological
study [37]). However, all three meta-epidemiological studies were small and two focused on
meta-analyses in only one clinical area, so the results may have limited generalisability.
Bias due to participants switching interventions within the trial and being analysed in a
group different from the one to which they were randomized was examined in one small meta-
epidemiological study of 12 meta-analyses in critical care medicine [48]. The ROR for mortality
effect estimates was 0.89 (95% CI 0.61 to 1.31).
Bias due to missing/incomplete outcome data. We did not combine estimates of average
bias due to attrition because the definition of attrition varied across the meta-epidemiological
studies (see S1 Appendix). Attrition was associated with overestimation of effect estimates in
some meta-epidemiological studies and underestimation in others, regardless of the type of
outcome (Fig 8). For example, reporting the use of a “modified” intention-to-treat (mITT)
analysis (versus ITT) was associated with exaggeration of intervention effect estimates (ROR
0.80, 95% CI 0.69 to 0.94; 1 meta-epidemiological study [32]), but having a dropout rate>20%
(versus20%) was not (ROR 1.07, 95% CI 0.92 to 1.25; 1 meta-epidemiological study [21]).
Fig 5. Random-effects meta-analysis of RORs and dSMDs associated with presence (versus absence) of baseline imbalance. The
Unverzagt 2013a ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, double blinding,
attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, switching interventions, sufficient follow-up, and single-
versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.92 (0.80, 1.06)].
doi:10.1371/journal.pone.0159267.g005
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The variation in average bias estimates across meta-analyses also differed between the meta-
epidemiological studies (Table 3).
Bias in measurement of outcomes. The influence of lack of/unclear blinding of outcome
assessors (versus blinding) was negligible in a meta-analysis of four meta-epidemiological stud-
ies [29,34,35,37] which analysed objective and subjective outcomes together (ROR 1.01, 95%
CI 0.90 to 1.13; I2 0%; Fig 9). In contrast, intervention effect estimates were exaggerated in trials
with unblinded (versus blinded) assessment of subjective binary (ROR 0.64, 95% CI 0.43 to
0.96; 1 meta-epidemiological study [11]), continuous (dSMD -0.23, 95% CI -0.40 to -0.06; 1
meta-epidemiological study [39]) and time-to-event outcomes (RHR 0.73, 95% CI 0.57 to 0.93;
1 meta-epidemiological study [40]). There was moderate inconsistency in average bias in these
three meta-epidemiological studies (I2 range 24% to 46%) (Table 3).
Lack of/unclear double blinding (versus double blinding, where both participants and per-
sonnel/assessors are blinded) was associated with a 23% exaggeration of intervention effect
estimates in trials with subjective outcomes (ROR 0.77, 95% CI 0.61 to 0.93; 1 meta-epidemio-
logical study [21]). In contrast, there was little evidence of such bias in trials of mortality or
other objective outcomes, or when all outcomes were analysed (ROR 0.92, 95% CI 0.74 to 1.14;
Fig 6. Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of participants (versus blinding of
participants).
doi:10.1371/journal.pone.0159267.g006
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I2 33%; 2 meta-epidemiological studies [21,42]; Fig 10). In the BRANDO study, there was an
increase in between-trial heterogeneity in trials with no/unclear (versus clear) double blinding,
and the average bias varied between meta-analyses (Table 3).
In one meta-epidemiological study, blinding of data analysts was recorded, but average bias
could not be quantified because the number of informative meta-analyses (i.e. those including
trials with and without the characteristic) was too low [29]. No meta-epidemiological study
examined bias due to use of faulty measurement instruments (with low validity and reliability).
Bias in selection of the reported result. Based on a meta-analysis of two small meta-epi-
demiological studies [34,37], there was no convincing evidence that trials rated at high/unclear
(versus low) risk of bias due to selective reporting have larger effect estimates (ROR 0.71, 95%
CI 0.43 to 1.19; Fig 11), but the inconsistency in estimates was high (I2 83%). Trials were only
rated at high risk of bias if any outcome domain was inconsistent between the methods and
results section. This differs from the scenario where the reported effect estimate has been
selected from among multiple measures or analyses (e.g. trialists perform multiple adjusted
analyses yet only report that which yielded the most favourable effect). Such bias in selection of
the reported result was not investigated in any of the included meta-epidemiological studies.
Discussion
This review of 24 meta-epidemiological studies suggests that on average, intervention effect
estimates are exaggerated in trials with inadequate/unclear (versus adequate) sequence genera-
tion and allocation concealment. For these characteristics, the average bias appears to be larger
Fig 7. Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of personnel or participants/
personnel (versus blinding of either party).
doi:10.1371/journal.pone.0159267.g007
Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review
PLOSONE | DOI:10.1371/journal.pone.0159267 July 11, 2016 17 / 26
Fig 8. Estimated RORs and dSMDs associated with any (versus no or minimal) attrition. The boxed section displays the average bias estimates,
where available, from the four meta-epidemiological studies contributing to the BRANDO 2012 study. The Abraha 2015a ROR is based on a multivariable
analysis with adjustment for use of placebo comparison, sample size, type of centre, items of risk of bias, post-randomisation exclusions, funding, and
publication bias [the corresponding univariable ROR (95% CI) is 0.83 (0.71, 0.97)]. The Unverzagt 2013b ROR is based on a multivariable analysis with
adjustment for sequence generation, allocation concealment, double blinding, selective outcome reporting, early stopping, pre-intervention, competing
interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR
(95% CI) is 1.19 (0.98, 1.45)]. The Nuesch 2009bc dSMD is based on a multivariable analysis with adjustment for allocation concealment [the
corresponding multivariable dSMD (95% CI) with adjustment for blinding of participants is -0.15 (-0.30, 0.00), and the corresponding univariable dSMD
(95% CI) is -0.13 (-0.29, 0.04)].
doi:10.1371/journal.pone.0159267.g008
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in trials of subjective outcomes compared with other objective outcomes. For subjective out-
comes, intervention effect estimates appear to be exaggerated in trials with lack of/unclear
blinding of participants (versus blinding of participants), lack of/unclear blinding of outcome
assessors (versus blinding of outcome assessors) and lack of/unclear double blinding (versus
double blinding, where both participants and personnel/assessors are blinded). The average
bias due to attrition varied depending on how it was defined. The influence of other character-
istics (baseline imbalance, no adjustment for confounders, use of block randomisation in
unblinded trials, unblinded personnel, and analysing participants in a group different from the
one to which they were randomized) is uncertain, because they have been examined in only a
few small meta-epidemiological studies. Some characteristics have not been investigated in any
meta-epidemiological study (unblinded data analysts, use of faulty measurement instruments,
bias in selection of the reported results). Only one meta-epidemiological study measured the
between-trial heterogeneity associated with characteristics [21], which was increased in trials
without double blinding, but less so in trials with inadequate/unclear sequence generation, allo-
cation concealment and attrition. The average bias estimates within meta-epidemiological
studies examining the impact of sequence generation, allocation concealment, patient blinding,
outcome assessor blinding, double blinding and attrition varied.
Fig 9. Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of outcome assessors (versus
blinding of outcome assessors). RHR = Ratio of hazard ratios. Hróbjartsson 2014aa “standard trials” comprise those comparing experimental
interventions with standard control interventions, such as placebo, no-treatment, usual care or active control. Hróbjartsson 2014ab “atypical trials”
comprise those comparing an oral experimental administration of a drug with the intravenous control administration of the same drug for
cytomegalovirus retinitis.
doi:10.1371/journal.pone.0159267.g009
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Our review builds on previous reviews [6,7] in several ways. We only included meta-epide-
miological studies adopting a matched design, as these provide the most reliable evidence of
the influence of reported study design characteristics on intervention effects [10]. We included
10 meta-epidemiological studies that were not included in the two previous reviews [32–
35,37,39–41,46,48]. Rather than presenting only the average bias estimate of each meta-
Fig 10. Random-effects meta-analysis of RORs associated with lack of/unclear double blinding (versus double blinding). The boxed
section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a
study (however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis
with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.87 (0.79, 0.96)]. The
BRANDO 2012b ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the
corresponding univariable ROR (95% CrI) is 0.92 (0.80, 1.04)]. The Unverzagt 2013c ROR is based on a multivariable analysis with adjustment for
sequence generation, allocation concealment, attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, baseline
imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.84
(0.69, 1.02)]. The BRANDO 2012d ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment
[the corresponding univariable ROR (95%CrI) is 0.93 (0.74, 1.18)]. The BRANDO 2012e ROR is based on a multivariable analysis with adjustment
for sequence generation and allocation concealment [the corresponding univariable ROR (95%CrI) is 0.78 (0.65, 0.92)].
doi:10.1371/journal.pone.0159267.g010
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epidemiological study (as was done in [6,7]), which can be difficult for readers to interpret, we
synthesised the average bias estimates for eight characteristics in random-effects meta-analyses.
We concur with the previous AHRQ review [6] that lack of outcome assessor blinding and
double blinding may exaggerate intervention effect estimates, yet we derived a more precise
estimate of the influence of inadequate sequence generation and allocation concealment than
the previous investigators. Ours is also the first systematic review to summarise estimates of
between-trial heterogeneity associated with study characteristics, and variation in average bias
across meta-analyses. The former was measured in only one meta-epidemiological study while
the latter was measured in 11 (46%) meta-epidemiological studies. This low frequency is a
shame because both features provide valuable data on whether certain methodological charac-
teristics lead not only to bias, but also to more variation in trial effect estimates, and whether
the average bias estimates are consistent across meta-analyses regardless of clinical area/inter-
vention/type of outcome.
Our review has some limitations. We only considered methodological characteristics
implied by the conceptual framework underlying the current Cochrane risk of bias tool for ran-
domized trials, because it is unclear whether other characteristics investigated in meta-
Fig 11. Random-effects meta-analysis of RORs and dSMDs associated with high/unclear (versus low) risk of bias due to selective
reporting. The Unverzagt 2013a ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment,
double blinding, attrition, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up,
and single- versus multi-centre status [the corresponding univariable ROR (95%CI) is 0.73 (0.54, 0.98)].
doi:10.1371/journal.pone.0159267.g011
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epidemiological studies (e.g. single-versus multi-centre status, early stopping) represent a spe-
cific bias, small-study effects, or spurious findings [54]. We relied on the existing AHRQ review
by Berkman et al. [6] to identify meta-epidemiological studies published before 2012, rather
than performing our own systematic search. Their search strategy was comprehensive, so we
believe it is unlikely that we have missed earlier meta-epidemiological studies. We did not con-
tact the authors of the included meta-epidemiological studies for a list of the meta-analyses/tri-
als examined in their study, so cannot determine the number of overlapping meta-analyses/
trials included in our analyses. However, the eligibility criteria described by the authors sug-
gests that the included meta-epidemiological studies examined meta-analyses/trials conducted
in clinical areas and published in years that differed from one another, and that differed from
those included in the BRANDO study, which ensured no overlap between its constituent meta-
epidemiological studies. Therefore, we believe that the frequency of overlapping meta-analy-
ses/trials in our meta-analyses is likely to be small.
There are also important limitations of the included meta-epidemiological studies. Many
meta-epidemiological studies examined a small number of meta-analyses, and so may have
had insufficient power to reliably estimate associations [55]. Estimates of average bias due to
one characteristic (e.g. allocation concealment) may be confounded by differences in other
characteristics (e.g. lack of blinded participants, sample size). Few meta-epidemiological studies
adjusted for confounders or adopted a within-trial design which reduced potential for con-
founding (e.g. [11]). Assessment of characteristics is often entirely based on what is reported in
papers, and reported methods do not always reflect actual conduct [56,57]. Therefore, it
remains unclear whether inadequate methods truly cause bias in intervention effect estimates
or are an artefact of incomplete reporting of trials or confounding (or both). To improve the
evidence base, future meta-epidemiological studies should report both univariable and multi-
variable analyses that adjust for potential confounders and, where available, assess risk of bias
based on the more detailed methods that are often reported in trial protocols as well as meth-
ods reported in publications [58].
We encourage decision makers and systematic reviewers who rely on the results of random-
ized trials to routinely consider the risk of biases associated with the methods used. Our review
suggests that particular caution is needed when interpreting the results of trials in which
sequence generation, allocation concealment and blinding are not reported, and when outcome
measures are subjectively assessed. This evidence is currently being taken into consideration in
our work on a revision of the Cochrane risk of bias tool for randomized trials, which will
include a new structure and clearer guidance that we anticipate will lead to more robust
assessments.
Novel approaches are needed to examine the influence of attrition and selective reporting.
Most previous meta-epidemiological studies of the influence of attrition have dichotomised tri-
als based on some arbitrary amount of missing data (e.g.>20%). It would be more useful to
know whether average bias varies according to different amounts of and reasons for missing
data. Further, in previous meta-epidemiological studies of selective reporting, the authors only
examined whether omission or addition of any trial outcome between the methods and results
section biases the result for the primary outcome of the review. This approach is based on an
assumption that selective reporting of any outcome leads to biased effect estimates for all out-
comes. It is more informative to know whether the specific trial effect estimates that are
assumed/known to have been selectively reported (e.g. because post-hoc, questionable analysis
methods were used) are systematically different from trial effect estimates assumed/known to
have not been selectively reported. No such investigation was conducted in any of the meta-
epidemiological studies included in our review.
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In conclusion, empirical evidence suggests that the following characteristics of randomized
trials are associated with exaggerated intervention effect estimates: inadequate/unclear (versus
adequate) sequence generation and allocation concealment, and no/unclear blinding of partici-
pants, blinding of outcome assessors and double blinding. The average bias appears to be great-
est in trials of subjective outcomes. More research on the influence of attrition and biased
reporting of results is needed. The development of novel methodological approaches for the
empirical investigation of study design biases would also be valuable.
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